Innate Pharma S.A. (IPHYF)
| Market Cap | 198.76M +0.8% |
| Revenue (ttm) | 10.57M -55.2% |
| Net Income | -57.74M |
| EPS | -0.65 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,700 |
| Open | 1.650 |
| Previous Close | 2.250 |
| Day's Range | 1.650 - 1.650 |
| 52-Week Range | 1.310 - 2.250 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 17, 2026 |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
As previously reported, Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3, citing enthusiasm for the company’s wholly-owned IPH4502. The…
Innate Pharma upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3.
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Innate Pharma (IPHA) to $7 from $5 and keeps a Buy rating on the shares. Innate Pharma’s lacutamab partnership…
Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO
(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initi...
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
Sobi and Innate Pharma (IPHA) announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key…
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
Innate also announced the appointment of Markus Jensen as chief medical officer and member of the executive leadership team, effective September 1, succeeding Sonia Quaratino. Jensen joined Innate Pha...
Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutane...
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have...
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its ...
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today...
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference.
Innate Pharma (IPHA) Completes Enrollment for Phase 1 Study of IPH4502
Innate Pharma (IPHA) Completes Enrollment for Phase 1 Study of IPH4502
Innate Pharma completes enrollment in dose escalation of IPH4502 study
Innate Pharma (IPHA) announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502, its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end…
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its...
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Outcome of Innate Pharma's 2026 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.
Innate Pharma to participate in the Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to Participate in the Jefferies Global Healthcare Conference.
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 ...
Innate Pharma Earnings Call Transcript: Q1 2026
Strong progress on three clinical assets, with lacutamab phase III and IPH4502 phase I advancing and key data readouts expected in H2 2026. AstraZeneca partnerships offer substantial milestone and royalty potential, while commercial opportunities in CTCL and urothelial cancer remain robust.
Innate Pharma Earnings release: Q1 2026
Innate Pharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q1 2026
Innate Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Innate Pharma Earnings release: Q1 2026
Innate Pharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated ...
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.